This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment of patients with ultra-rare disorders. The company’s complement franchise consists of key growth driver, Soliris, which is approved for the treatment of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system — paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is also approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA also approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of adult patients with PNH, to be administered every eight weeks. In October 2019, the FDA approved the use of Ultomiris as a treatment for adult and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.
How Will Biotech ETFs React to These Q1 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Company News for May 3, 2021
by Zacks Equity Research
Companies In The News Are: AON, ALXN, CLX, QSR.
Alexion Pharmaceuticals (ALXN) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Alexion (ALXN) delivered earnings and revenue surprises of 14.29% and 4.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Alexion (ALXN) Tops Q1 Earnings, Merger With AstraZeneca On Track
by Zacks Equity Research
Alexion (ALXN) tops earnings and sales in the first quarter of 2021. Its merger with AstraZeneca is expected to close in the third quarter.
AstraZeneca (AZN) Q1 Earnings Top, COVID-19 Vaccine Adds $275M
by Zacks Equity Research
AstraZeneca (AZN) surpasses first-quarter estimates on both counts. Stock up in pre-market.
Apellis' (APLS) Q1 Earnings Miss, Pegcetacoplan in Focus
by Zacks Equity Research
Apellis' (APLS) earnings lag estimates in the first quarter of 2021. Main focus of the company is on its lead pipeline candidate, pegcetacoplan.
Analysts Estimate Alexion Pharmaceuticals (ALXN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Alexion (ALXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alexion (ALXN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion (ALXN) is set to provide updates on revenues and earnings when it releases first-quarter 2021 results on May 3.
Alexion Pharmaceuticals (ALXN) is Overbought: Is A Drop Coming?
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) has moved higher as of late, but there could definitely be trouble on the horizon for this company.
AstraZeneca (AZN) Gets FTC Clearance for Alexion Acquisition
by Zacks Equity Research
AstraZeneca (AZN) obtains U.S. Federal Trade Commission's permission for the Alexion acquisition. The deal is expected to close in the third quarter of 2021.
Alexion (ALXN) Moves 3.9% Higher: Will This Strength Last?
by Zacks Equity Research
Alexion (ALXN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Immunovant (IMVT) Gains on a Potential Buyout by Roivant
by Zacks Equity Research
Immunovant (IMVT) gains following Roivant's announcement of a possible buyout of the company. Roivant is a major stakeholder of Immunovant.
Why Is Alexion (ALXN) Down 3.5% Since Last Earnings Report?
by Zacks Equity Research
Alexion (ALXN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Apellis' (APLS) Q4 Earnings Rise Y/Y, Pegcetacoplan in Focus
by Zacks Equity Research
Apellis' (APLS) bottom line grows year over year in the fourth quarter of 2020 while revenues beat estimates. Main focus of the company is on lead pipeline candidate, pegcetacoplan.
Nasdaq ETF's Worst Day Since October: Stocks That Survived
by Sanghamitra Saha
The Nasdaq dropped 3.52% on Feb 25 for its worst session since October on rising rate worries. However, some stocks still remained in the green on that day or lost little.
Zacks.com featured highlights include: Sanmina Corp, Canadian Solar, Celestica and Alexion Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights include: Sanmina Corp, Canadian Solar, Celestica and Alexion Pharmaceuticals
Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) beats both earnings and sales estimates in the fourth quarter of 2020.
Prothena's (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Prothena (PRTA) beats on earnings in the fourth quarter of 2020 and surpasses sales estimates too.
Ultragenyx (RARE) Q4 Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports a narrower year-over-year loss and sales beat estimates in the fourth quarter of 2020.
Pick These 4 Low P/CF Stocks for a Value-Based Portfolio
by Sumit Singh
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Sanmina Corporation (SANM), Canadian Solar (CSIQ), Celestica (CLS) and Alexion Pharmaceuticals (ALXN) boast low P/CF ratio.
Gilead (GILD) & Galapagos Discontinue Development of IPF Drug
by Zacks Equity Research
Gilead (GILD) and partner Galapagos announce their decision to discontinue development of ziritaxestat in patients with idiopathic pulmonary fibrosis.
ALXN vs. BMRN: Which Stock Is the Better Value Option?
by Zacks Equity Research
ALXN vs. BMRN: Which Stock Is the Better Value Option?
5 Best PEG-Driven Value Stocks Amid COVID-Led Uncertainty
by Urmimala Biswas
Here are five of the 61 value stocks with discounted PEG.
AstraZeneca (AZN) Q4 Earnings, Sales Top Despite COVID-19 Woes
by Zacks Equity Research
AstraZeneca (AZN) surpasses fourth-quarter estimates on both counts. Stock up in pre-market.
Palatin (PTN) Jumps: Stock Rises 8.7%
by Zacks Equity Research
Palatin (PTN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.